Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 91Carcinoma, Non-Small-Cell Lung 84Neoplasms 48Carcinoma, Renal Cell 44Neoplasm Metastasis 40Carcinoma, Hepatocellular 36Squamous Cell Carcinoma of Head and Neck 35Colorectal Neoplasms 31Pancreatic Neoplasms 24Lung Neoplasms 20Stomach Neoplasms 19Head and Neck Neoplasms 18Carcinoma, Transitional Cell 17Hodgkin Disease 16Breast Neoplasms 16Small Cell Lung Carcinoma 15Ovarian Neoplasms 14Urinary Bladder Neoplasms 13Recurrence 13Advanced Cancer 13Glioblastoma 12Brain Neoplasms 12Lymphoma 11Kidney Neoplasms 11Glioma 11Prostatic Neoplasms 10Lymphoma, Non-Hodgkin 10Uveal Melanoma 9Triple Negative Breast Neoplasms 9Sarcoma 9

Interventions

Temozolomide 13Filgrastim 8Carboplatin 8Radiotherapy 7Magnetic Resonance Spectroscopy 7Etoposide 7Cisplatin 7Cyclophosphamide 6Bevacizumab 6Vincristine 4Thiotepa 4Carmustine 4sargramostim 3Surveys and Questionnaires 3Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Lapatinib 3Irinotecan 3Azacitidine 3veliparib 2alovudine 2aldesleukin 2Tamoxifen 2Radiotherapy, Conformal 2Radiation 2Paclitaxel 2Mental Status and Dementia Tests 2Imatinib Mesylate 2Granulocyte-Macrophage Colony-Stimulating Factor 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ependymoma × Nivolumab × Clear all
NCT03173950 2025-06-29

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
133 enrolled
CNS

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningioma, Pinealoma, Spinal Cord Neoplasms, Choroid Plexus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡